Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN β-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis
Interferon β-1a (IFNβ1a) is considered safe in relapsing-remitting multiple sclerosis (RRMS). Drug-induced thrombocytopenia (DITP) is a rare but underreported adverse event that is often confused with other causes of thrombocytopenia. We report the case of a 52-year-old woman who developed limb and...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2022/2767031 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548820588691456 |
|---|---|
| author | Christophe Cisarovsky Marie Théaudin Pierre-Alexandre Bart Grégoire Stalder Lorenzo Alberio |
| author_facet | Christophe Cisarovsky Marie Théaudin Pierre-Alexandre Bart Grégoire Stalder Lorenzo Alberio |
| author_sort | Christophe Cisarovsky |
| collection | DOAJ |
| description | Interferon β-1a (IFNβ1a) is considered safe in relapsing-remitting multiple sclerosis (RRMS). Drug-induced thrombocytopenia (DITP) is a rare but underreported adverse event that is often confused with other causes of thrombocytopenia. We report the case of a 52-year-old woman who developed limb and oral mucosa petechiae and hematochezia, 10 years after beginning IFNβ1a. Blood work showed an isolated severe thrombocytopenia and ruled out other autoimmune diseases, viral infections, intravascular hemolysis, and renal impairment. Oral corticosteroids and tranexamic acid were initiated with a favorable platelet response. IFNβ1a was resumed, leading to recurrence of thrombocytopenia. Platelets came back to normal after intravenous immunoglobulins and IFNβ1a was definitively discontinued. To our knowledge, this is the first case of drug-induced immune thrombocytopenia (DITP) associated with IFNβ1a. |
| format | Article |
| id | doaj-art-64a750a79c654658bd8f713292cd3e73 |
| institution | Kabale University |
| issn | 2090-6579 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-64a750a79c654658bd8f713292cd3e732025-02-03T06:13:03ZengWileyCase Reports in Hematology2090-65792022-01-01202210.1155/2022/2767031Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN β-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple SclerosisChristophe Cisarovsky0Marie Théaudin1Pierre-Alexandre Bart2Grégoire Stalder3Lorenzo Alberio4Division of Internal MedicineDivision of NeurologyDivision of Internal MedicineService and Central Laboratory of HematologyService and Central Laboratory of HematologyInterferon β-1a (IFNβ1a) is considered safe in relapsing-remitting multiple sclerosis (RRMS). Drug-induced thrombocytopenia (DITP) is a rare but underreported adverse event that is often confused with other causes of thrombocytopenia. We report the case of a 52-year-old woman who developed limb and oral mucosa petechiae and hematochezia, 10 years after beginning IFNβ1a. Blood work showed an isolated severe thrombocytopenia and ruled out other autoimmune diseases, viral infections, intravascular hemolysis, and renal impairment. Oral corticosteroids and tranexamic acid were initiated with a favorable platelet response. IFNβ1a was resumed, leading to recurrence of thrombocytopenia. Platelets came back to normal after intravenous immunoglobulins and IFNβ1a was definitively discontinued. To our knowledge, this is the first case of drug-induced immune thrombocytopenia (DITP) associated with IFNβ1a.http://dx.doi.org/10.1155/2022/2767031 |
| spellingShingle | Christophe Cisarovsky Marie Théaudin Pierre-Alexandre Bart Grégoire Stalder Lorenzo Alberio Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN β-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis Case Reports in Hematology |
| title | Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN β-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis |
| title_full | Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN β-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis |
| title_fullStr | Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN β-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis |
| title_full_unstemmed | Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN β-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis |
| title_short | Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN β-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis |
| title_sort | severe late onset drug induced immune thrombocytopenia following ifn β 1a treatment a case report of a 52 year old woman with relapse remitting multiple sclerosis |
| url | http://dx.doi.org/10.1155/2022/2767031 |
| work_keys_str_mv | AT christophecisarovsky severelateonsetdruginducedimmunethrombocytopeniafollowingifnb1atreatmentacasereportofa52yearoldwomanwithrelapseremittingmultiplesclerosis AT marietheaudin severelateonsetdruginducedimmunethrombocytopeniafollowingifnb1atreatmentacasereportofa52yearoldwomanwithrelapseremittingmultiplesclerosis AT pierrealexandrebart severelateonsetdruginducedimmunethrombocytopeniafollowingifnb1atreatmentacasereportofa52yearoldwomanwithrelapseremittingmultiplesclerosis AT gregoirestalder severelateonsetdruginducedimmunethrombocytopeniafollowingifnb1atreatmentacasereportofa52yearoldwomanwithrelapseremittingmultiplesclerosis AT lorenzoalberio severelateonsetdruginducedimmunethrombocytopeniafollowingifnb1atreatmentacasereportofa52yearoldwomanwithrelapseremittingmultiplesclerosis |